Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCB303 in advanced malignancies
NCT07859228Phase 1Not yet recruiting
- Sponsor
- FBD Biologics Limited
- Start
- Feb 2027
- Primary completion
- Feb 2029
01
Overview
Phase 1, open-label, single-arm trial of HCB303 in solid tumor (advanced stage), sponsored by FBD Biologics Limited. Primary endpoint: Maximum Tolerated Dose and Recommended Dose for Expansion at 28 days. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
HCB303
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07859228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07859228.